Emory University Hospital, Atlanta, GA, USA.
CIBMTR (Center for International Blood and Marrow Transplant Research), Department of Medicine, Medical College of Wisconsin, Milwaukee, WI, USA.
Haematologica. 2017 Nov;102(11):1823-1832. doi: 10.3324/haematol.2017.169581. Epub 2017 Aug 17.
Advances in allogeneic hematopoietic cell transplantation for sickle cell disease have improved outcomes, but there is limited analysis of healthcare utilization in this setting. We hypothesized that, compared to late transplantation, early transplantation (at age <10 years) improves outcomes decreases healthcare utilization. We performed a retrospective study of children transplanted for sickle cell disease in the USA during 2000-2013 using two large databases. Univariate and Cox models were used to estimate associations of demographics, sickle cell disease severity, and transplant-related variables with mortality and chronic graft--host disease, while Wilcoxon, Kruskal-Wallis, or linear trend tests were applied for the estimates of healthcare utilization. Among 161 patients with a 2-year overall survival rate of 90% (95% confidence interval [CI] 85-95%) mortality was significantly higher in those who underwent late transplantation versus early (hazard ratio (HR) 21, 95% CI 2.8-160.8, =0.003) and unrelated compared to matched sibling donor transplantation (HR 5.9, 95% CI 1.7-20.2, =0.005). Chronic graftversus host disease was significantly more frequent among those translanted late (HR 1.9, 95% CI 1.0-3.5, =0.034) and those who received an unrelated graft (HR 2.5, 95% CI 1.2-5.4; =0.017). Merged data for 176 patients showed that the median total adjusted transplant cost per patient was $467,747 (range: $344,029-$799,219). Healthcare utilization was lower among recipients of matched sibling donor grafts and those with low severity disease compared to those with other types of donor and disease severity types (<0.001 and =0.022, respectively); no association was demonstrated with late transplantation (=0.775). Among patients with 2-year pre- and post-transplant data (n=41), early transplantation was associated with significant reductions in admissions (<0.001), length of stay (<0.001), and cost (=0.008). Early transplant outcomes need to be studied prospectively in young children without severe disease and an available matched sibling to provide conclusive evidence for the superiority of this approach. Reduced post-transplant healthcare utilization inpatient care indicates that transplantation may provide a sustained decrease in healthcare costs over time.
异体造血细胞移植治疗镰状细胞病的进展改善了预后,但对此种情况下的医疗保健利用情况的分析有限。我们假设与晚期移植相比,早期移植(<10 岁)可改善预后并减少医疗保健的利用。我们使用两个大型数据库对美国 2000 年至 2013 年间接受镰状细胞病移植的儿童进行了回顾性研究。单变量和 Cox 模型用于估计人口统计学,镰状细胞病严重程度和移植相关变量与死亡率和慢性移植物抗宿主病的关系,而 Wilcoxon,Kruskal-Wallis 或线性趋势检验用于医疗保健利用的估计。在 161 例 2 年总生存率为 90%(95%置信区间[CI]85-95%)的患者中,晚期与早期(危险比[HR]21,95%CI 2.8-160.8,=0.003)和非亲缘供体与匹配的同胞供体移植相比,死亡率显著更高(HR 5.9,95%CI 1.7-20.2,=0.005)。晚期移植(HR 1.9,95%CI 1.0-3.5,=0.034)和接受非亲缘供体移植物的患者中慢性移植物抗宿主病的发生率明显更高(HR 2.5,95%CI 1.2-5.4;=0.017)。176 例患者合并数据显示,每位患者的中位总调整后移植费用为 467747 美元(范围:344029-799219 美元)。与其他供体和疾病严重程度类型的受者相比,接受匹配的同胞供体移植物和低严重程度疾病的受者的医疗保健利用率较低(<0.001 和=0.022);与晚期移植无关(=0.775)。在具有 2 年移植前和移植后数据的 41 例患者中,早期移植与入院率(<0.001),住院时间(<0.001)和成本(=0.008)的显著降低有关。对于没有严重疾病和可用匹配同胞的年轻儿童,需要前瞻性研究早期移植的结果,以提供该方法优越性的确凿证据。移植后医疗保健利用率(住院治疗)的降低表明,随着时间的推移,移植可能会持续降低医疗保健成本。